Dosing Starts in Athira’s Phase 2 ACT-AD Trial Testing ATH-1017; Enrollment Ongoing
News
Athira Pharma has begun dosing patients in its Phase 2 clinical trial evaluating ATH-1017, an investigational small molecule for the treatment of mild to moderate Alzheimer’s disease. Clinical efficacy ... Read more